Company: MLTX
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001140361-25-014923
Chunk: 44

Company: MoonLake Immunotherapeutics
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 44
---
 31, 2024 plus the target bonus opportunity. Based on the CACM methodology described above, we identified the median employee and calculated the fiscal 2024 compensation for this selected employee in the same manner we determine the annual total compensation of our NEOs for purposes of the Summary Compensation Table. The median of the annual total compensation of all our employees was $128,943. Dr. Santos da Silva’s fiscal 2024 annual total compensation as disclosed in the 2024 Summary Compensation Table was $1,406,038. As a result, our CEO to median employee pay ratio for fiscal 2024 is 10.9:1. This pay ratio is a reasonable estimate calculated by a method consistent with the SEC requirements, described above, based on our payroll and employment records. As a result of a variety of factors, including employee populations, potential differences in the components used for the CACM, compensation philosophies and certain assumptions, pay ratios reported by other companies may not be comparable to our pay ratio. The pay ratio is not utilized by our management or our Compensation Committee for compensation-related decisions. 30

TABLE OF CONTENTS

Pay Versus Performance As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item 402(v) of Regulation S-K, we are providing the following information about the relationship between executive compensation actually paid and certain financial performance of the Company.

| Year |             |     |      Summary 
 Compensation 
  Table Total 
     for PEO1 |       |     |  Compensation 
 Actually Paid 
       to PEO2 |     |      Average 
      Summary 
 Compensation 
  Table Total 
  for Non-PEO 
        NEOs3 |     |       Average 
  Compensation 
 Actually Paid 
    to Non-PEO 
         NEOs4 |     |      Value of 
 Initial Fixed 
          $100 
    Investment 
     Based On: |     |       |     | Net Loss7      |     | Company- 
 Selected 
 Measure8 |
|      | Total       
 Shareholder 
 Return      
 (“TSR”)5    |     |              | Peer  
 Group 
 TSR6  |     |               |     |              |     |               |     |               |     |       |     |                |     |          |
| 2024 |             |     |   $1,406,038 |       |     |    $(225,066) |     |   $1,